Skip to main content
Erschienen in: Pathology & Oncology Research 1/2019

13.10.2017 | Original Article

Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results

verfasst von: Anikó Maráz, András Csejtei, Judit Kocsis, Miklós Szűcs, Zsuzsanna Kahán, György Bodoky, Magdolna Dank, László Mangel, János Révész, Zoltán Varga, Lajos Géczi

Erschienen in: Pathology & Oncology Research | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Everolimus is indicated for adults with metastatic renal cell carcinoma (mRCC) after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (TKI). Currently, the therapeutic applicability of EVE has been changing. Multicenter evaluation of efficacy and safety of everolimus in daily routine and definition of patient characteristics with favorable outcome. Data of 165 patients from 9 oncology institutes in Hungary were analyzed retrospectively. Everolimus therapy was used after one TKI in 10 mg starting dose. Physical and laboratory examinations and imaging tests were performed monthly and every 3 months, respectively. Median progression-free survival (PFS) was 5.4 months. Median overall survival (OS) was 16.2 months. PFS and OS results were more favorable in patients with ECOG 0–1 (pPFS = 0.033, pOS = 0.008) and after >9 months of TKI therapy (pPFS = 0.019, pOS = 0.045). Survival was longer in nonanemic patients with ECOG 0–1 than in anemic patients with ECOG 2–3, 30.9 and 7.7 months, respectively (p = 0.029). Dose reduction and treatment delay was required in 6.2% and 8.9% of patients, respectively. Common adverse events were exanthema, edema, stomatitis, anemia, and abnormal kidney functions and glucose levels. Results of this study show that everolimus is safe and efficacious in a real-world setting. Everyday practice showed that nonanemic patients with good performance status receiving TKI therapy for >9 months are favorable candidates for this treatment. Despite the efficiency of novel, registered drugs, everolimus still plays an important role during and after second-line therapy for mRCC when availability of modern remedies is limited.
Literatur
3.
Zurück zum Zitat Eisen HJ, Tuzcu M, Dorent R et al (2003) Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant patients. N Engl J Med 349:847–858CrossRefPubMed Eisen HJ, Tuzcu M, Dorent R et al (2003) Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant patients. N Engl J Med 349:847–858CrossRefPubMed
4.
Zurück zum Zitat Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456CrossRefPubMed Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456CrossRefPubMed
6.
Zurück zum Zitat Yao JC, Fazio N, Singh S et al (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387:968–977CrossRefPubMed Yao JC, Fazio N, Singh S et al (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387:968–977CrossRefPubMed
7.
Zurück zum Zitat Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520–529CrossRef Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520–529CrossRef
8.
Zurück zum Zitat Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:4256–4265CrossRef Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:4256–4265CrossRef
9.
Zurück zum Zitat Calvo E, Escudier B, Motzer RJ et al (2011) Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 48:333–339CrossRefPubMed Calvo E, Escudier B, Motzer RJ et al (2011) Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 48:333–339CrossRefPubMed
11.
Zurück zum Zitat Escudier B, Porta C, Schmidinger M et al (2014) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:49–56CrossRef Escudier B, Porta C, Schmidinger M et al (2014) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:49–56CrossRef
12.
Zurück zum Zitat Ljungberg B, Bensalah K, Canfield S et al (2015) EAU Guidelines on Renal Cell Carcinoma: 2014 Update. Eur Urol 67:913–924CrossRefPubMed Ljungberg B, Bensalah K, Canfield S et al (2015) EAU Guidelines on Renal Cell Carcinoma: 2014 Update. Eur Urol 67:913–924CrossRefPubMed
13.
Zurück zum Zitat Motzer RJ, Escudier B, McDermott DF, el al (2015) Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 373:1803–1813 Motzer RJ, Escudier B, McDermott DF, el al (2015) Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 373:1803–1813
14.
15.
Zurück zum Zitat Choueiri TK, Escudier B, Powles T et al (2016) Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17:917–927CrossRef Choueiri TK, Escudier B, Powles T et al (2016) Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17:917–927CrossRef
16.
Zurück zum Zitat Motzer RJ, Hutson TE, Glen H et al (2015) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomized, phase 2, open-label, multicenter trial. Lancet Oncol 16:1473–1482CrossRef Motzer RJ, Hutson TE, Glen H et al (2015) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomized, phase 2, open-label, multicenter trial. Lancet Oncol 16:1473–1482CrossRef
17.
Zurück zum Zitat Escudier B, Porta C, Schmidinger M et al (2016) Renal Cell Carcinoma: ESMO Clinical Practice Guidelines. Ann Oncol 27:58–68CrossRef Escudier B, Porta C, Schmidinger M et al (2016) Renal Cell Carcinoma: ESMO Clinical Practice Guidelines. Ann Oncol 27:58–68CrossRef
18.
Zurück zum Zitat Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–214CrossRefPubMed Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–214CrossRefPubMed
21.
Zurück zum Zitat Rini BI, Flaherty K (2008) Clinical effect and future considerations for molecularly-targeted therapy in renal cancer. Uro Oncol Semin Orig Investig 26:543–549 Rini BI, Flaherty K (2008) Clinical effect and future considerations for molecularly-targeted therapy in renal cancer. Uro Oncol Semin Orig Investig 26:543–549
22.
Zurück zum Zitat Grünwald V, Karakiewicz PI, Bavbek SE et al (2012) An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur J Cancer 48:324–332CrossRefPubMed Grünwald V, Karakiewicz PI, Bavbek SE et al (2012) An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur J Cancer 48:324–332CrossRefPubMed
23.
Zurück zum Zitat Calvo E, Ravaud A, Bellmunt J (2013) What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI? Cancer Treat. Rev. 39:366–374CrossRefPubMed Calvo E, Ravaud A, Bellmunt J (2013) What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI? Cancer Treat. Rev. 39:366–374CrossRefPubMed
24.
Zurück zum Zitat Bergmann L, Kube U, Doehn C et al (2015) Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study. BMC Cancer 15:303CrossRefPubMedPubMedCentral Bergmann L, Kube U, Doehn C et al (2015) Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study. BMC Cancer 15:303CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Motzer RJ, Bacik J, Schwartz LH et al (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454–463CrossRefPubMed Motzer RJ, Bacik J, Schwartz LH et al (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454–463CrossRefPubMed
Metadaten
Titel
Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results
verfasst von
Anikó Maráz
András Csejtei
Judit Kocsis
Miklós Szűcs
Zsuzsanna Kahán
György Bodoky
Magdolna Dank
László Mangel
János Révész
Zoltán Varga
Lajos Géczi
Publikationsdatum
13.10.2017
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 1/2019
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-017-0317-0

Weitere Artikel der Ausgabe 1/2019

Pathology & Oncology Research 1/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.